Clinical Diagnosis and Treatment of Immune-related Adverse Events of Edocrine System Related to Immune Checkpoint Inhibitors.
10.3779/j.issn.1009-3419.2019.10.08
- Author:
Lian DUAN
1
;
Linjie WANG
1
;
Xiaoyan SI
2
;
Li ZHANG
3
;
Xiaowei LIU
4
;
Yue LI
5
;
Hanping WANG
2
;
Xiaoxiao GUO
6
;
Jiaxin ZHOU
7
;
Huijuan ZHU
1
;
Li ZHANG
2
Author Information
1. Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730 Beijing, China.
2. Department of Respiratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730 Beijing, China.
3. Department of Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730 Beijing, China.
4. Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730 Beijing, China.
5. Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730 Beijing, China.
6. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730 Beijing, China.
7. Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 100730 Beijing, China.
- Publication Type:Journal Article
- Keywords:
Endocrine system;
Immune checkpoint inhibitors;
Immune-related adverse events
- From:
Chinese Journal of Lung Cancer
2019;22(10):649-652
- CountryChina
- Language:Chinese
-
Abstract:
As a new type of anti-cancer drugs, immune checkpoint inhibitors (ICIs) have shown remarkable therapeutic effects in many malignant tumors. By virtue of their targets and mechanisms of action, ICIs can cause autoimmune and inflammatory effects, termed immune-related adverse events (irAEs). Unlike traditional therapies, irAEs are latent and unstable. Severe adverse reactions will force patients to discontinue treatment and even affect their survival. Therefore, with the wide application of ICIs in clinical practice, clinicians need to fully understand the possible adverse reactions of such drugs and appropriate treatment strategies, in order to improve the survival rate and treatment effect of patients receiving ICIs. In this article, we review the incidence, clinical features, diagnosis and treatment of immune-related endocrine events that may occur with administration of ICIs.
